Delivery Order SPE2DB20D1100-SPE2DB25FE1CU
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Nucynta 100 mg tablets (100 count) with a ceiling value of $2,251.73. This firm fixed-price delivery order, with an ultimate completion date of August 21, 2025, represents a competitively awarded non-set-aside contract. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Nucynta 75 mg tablets (100 count) with a ceiling value of $2,451.24. This is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Nucynta 75 mg tablets (100 count) with a ceiling value of $1,432.38. This is a firm fixed-price delivery order with an ultimate completion date of August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competitively awarded. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order valued at $4,764.50 to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Nucynta 75 mg tablets (100 count). This firm fixed-price delivery order, with an ultimate completion date of September 26, 2025, represents a pediatric pain management pharmaceutical product for military healthcare needs. The award was made through open competition with no set-aside designation, and the product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Nucynta 75 mg tablets (100-count units) valued at $2,864.76, with an ultimate completion date of August 19, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,864.76 for 100 tablets of Nucynta 75 mg on June 2, 2025, with completion scheduled for June 3, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award represents a specific pharmaceutical delivery under DLA's medical supply chain operations, with performance to occur at the vendor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Nucynta 50 mg tablets (100 count) with a ceiling value of $1,225.04. This firm fixed-price delivery order, with an ultimate completion date of July 23, 2025, represents a direct fulfillment of pharmaceutical needs through the federal medical supply chain. The contract is not set-aside and was competitively awarded, reflecting AmerisourceBergen's established capability as a...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Nucynta ER 150 mg tablets (60-count units) with a contract ceiling value of $4,749.30. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through an open procurement process. The order is scheduled for ultimate completion on August 21, 2025, and will be fulfilled from AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Nucynta ER 100 mg tablets (60-count units) with a ceiling value of $1,472.04. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for ultimate completion on September 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Nucynta 50 mg tablets (100 units) with a ceiling value of $1,225.04. This competitively awarded, firm fixed-price delivery order is not subject to any set-aside designation and is scheduled for completion by September 5, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1CUDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Nucynta 75 mg tablets (100 count) on September 25, 2025, with a contract ceiling value of $4,482.56. This delivery order represents a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 26, 2025. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The primary IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, has demonstrated capability to fulfill federal requirements through open competition, serving defense and veteran healthcare systems with brand-name and generic medications across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 9/25/25 |